Tarsus Pharmaceuticals, Inc.
TARS
Hisse Senetlerindeki Sıralama
#4646
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Hisse Fiyatı
$69.68
Piyasa Değeri
$3.26B
Değişim (1 gün)
2.36%
Değişim (1 yıl)
-4.46%
Ülke
US
Ticaret Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Tarsus Pharmaceuticals, Inc. (TARS) için EPS
June 2026 itibariyle EPS TTM: $-1.09
Tarsus Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $-1.09'dir. 2023 yılı sonunda, şirketin EPS'si $-4.62 idi; bu, 2022 yılındaki EPS olan $-2.52 ile önceki yıla göre artış.
Tarsus Pharmaceuticals, Inc. için 2018 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
